{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:36:21Z","timestamp":1791196581969,"version":"4.1.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>EBV-positive nasopharyngeal carcinoma and Hodgkin, T, and natural killer (NK) lymphomas express EBNA-1 and the latent membrane proteins (LMP1-2; type II latency). In contrast to type III EBV-transformed lymphoblastoid cell lines, in these cells the LMPs are expressed in the absence of EBNA-2. We have previously reported that exposure to CD40 ligand and IL-4 could induce LMP-1 in an in vitro EBV-infected Hodgkin lymphoma-derived cell line, which expressed only EBNA-1. We show now that both human and EBV-encoded IL-10 can induce LMP-1 in the absence of EBNA-2 in the Daudi, P3HR1, and other BL cell lines. Interestingly, induction of LMP-1 was not accompanied by the downregulation of BCL-6. IL-10 could also induce LMP-1 in the conditional lymphoblastoid cell line ER\/EB2-5 where EBNA-2 was downregulated in the absence of estrogen. Moreover, IL-10 could induce the expression of LMP-1 in tonsillar B cells infected with the nontransforming, EBNA-2-deficient EBV strain P3HR1 and enhance LMP-1 expression in 2 EBV-positive NK lymphoma lines. The demonstration that IL-10 can induce the expression of LMP-1 in an EBNA-2-independent manner shows that the major transforming EBV gene LMP-1 can be induced by extracellular signals in lymphoid cells, and IL-10 might contribute to the establishment of type II EBV latency.<\/jats:p>","DOI":"10.1182\/blood-2005-06-2569","type":"journal-article","created":{"date-parts":[[2005,12,7]],"date-time":"2005-12-07T03:13:44Z","timestamp":1133925224000},"page":"2928-2935","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":75,"title":["IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines"],"prefix":"10.1182","volume":"107","author":[{"given":"Lorand L.","family":"Kis","sequence":"first","affiliation":[{"name":"From the Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Takahara","sequence":"additional","affiliation":[{"name":"From the Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Nagy","sequence":"additional","affiliation":[{"name":"From the Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Klein","sequence":"additional","affiliation":[{"name":"From the Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Klein","sequence":"additional","affiliation":[{"name":"From the Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111814522972200_REF1","doi-asserted-by":"crossref","unstructured":"Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Virology. Vol 2. New York, NY: Lippincott, Williams, and Wilkins; 2001: 2575-2628.","DOI":"10.1016\/S0168-1702(01)00436-1"},{"key":"2019111814522972200_REF2","doi-asserted-by":"crossref","unstructured":"Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1: 75-82.","DOI":"10.1038\/35095584"},{"key":"2019111814522972200_REF3","doi-asserted-by":"crossref","unstructured":"Fahraeus R, Fu HL, Ernberg I, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer. 1988;42: 329-338.","DOI":"10.1002\/ijc.2910420305"},{"key":"2019111814522972200_REF4","doi-asserted-by":"crossref","unstructured":"Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991;337: 320-322.","DOI":"10.1016\/0140-6736(91)90943-J"},{"key":"2019111814522972200_REF5","doi-asserted-by":"crossref","unstructured":"Harabuchi Y, Yamanaka N, Kataura A, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. 1990;335: 128-230.","DOI":"10.1016\/0140-6736(90)90002-M"},{"key":"2019111814522972200_REF6","doi-asserted-by":"crossref","unstructured":"Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A. 1993;90: 9150-9154.","DOI":"10.1073\/pnas.90.19.9150"},{"key":"2019111814522972200_REF7","doi-asserted-by":"crossref","unstructured":"Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 1998;17: 1700-1709.","DOI":"10.1093\/emboj\/17.6.1700"},{"key":"2019111814522972200_REF8","doi-asserted-by":"crossref","unstructured":"Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997;16: 6131-6140.","DOI":"10.1093\/emboj\/16.20.6131"},{"key":"2019111814522972200_REF9","doi-asserted-by":"crossref","unstructured":"Araujo I, Foss HD, Hummel M, et al. Frequent expansion of Epstein-Barr virus (EBV) infected cells in germinal centres of tonsils from an area with a high incidence of EBV-associated lymphoma. J Pathol. 1999;187: 326-330.","DOI":"10.1002\/(SICI)1096-9896(199902)187:3<326::AID-PATH242>3.0.CO;2-N"},{"key":"2019111814522972200_REF10","doi-asserted-by":"crossref","unstructured":"Kurth J, Spieker T, Wustrow J, et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity. 2000;13: 485-495.","DOI":"10.1016\/S1074-7613(00)00048-0"},{"key":"2019111814522972200_REF11","doi-asserted-by":"crossref","unstructured":"Niedobitek G, Agathanggelou A, Rowe M, et al. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood. 1995;86: 659-665.","DOI":"10.1182\/blood.V86.2.659.bloodjournal862659"},{"key":"2019111814522972200_","doi-asserted-by":"crossref","unstructured":"Carbone A, Gloghini A, Zagonel V, Tirelli U. Expression of Epstein-Barr virus encoded latent membrane protein 1 in nonendemic Burkitt's lymphomas. Blood. 1996;87: 1202-1204.","DOI":"10.1182\/blood.V87.3.1202b.bloodjournal8731202b"},{"key":"2019111814522972200_","doi-asserted-by":"crossref","unstructured":"Araujo I, Foss HD, Bittencourt A, et al. Expression of Epstein-Barr virus-gene products in Burkitt's lymphoma in Northeast Brazil. Blood. 1996;87: 5279-5286.","DOI":"10.1182\/blood.V87.12.5279.bloodjournal87125279"},{"key":"2019111814522972200_","doi-asserted-by":"crossref","unstructured":"Spina D, Leoncini L, Megha T, et al. Cellular kinetic and phenotypic heterogeneity in and among Burkitt's and Burkitt-like lymphomas. J Pathol. 1997;182: 145-150.","DOI":"10.1002\/(SICI)1096-9896(199706)182:2<145::AID-PATH819>3.0.CO;2-P"},{"key":"2019111814522972200_REF15","doi-asserted-by":"crossref","unstructured":"Xue SA, Labrecque LG, Lu QL, et al. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer. 2002;99: 635-643.","DOI":"10.1002\/ijc.10372"},{"key":"2019111814522972200_REF16","doi-asserted-by":"crossref","unstructured":"Cen H, Williams PA, McWilliams HP, Breinig MC, Ho M, McKnight JL. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood. 1993;81: 1393-1403.","DOI":"10.1182\/blood.V81.5.1393.1393"},{"key":"2019111814522972200_REF17","unstructured":"Oudejans JJ, Jiwa M, van den Brule AJ, et al. Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol. 1995;147: 923-933."},{"key":"2019111814522972200_REF18","doi-asserted-by":"crossref","unstructured":"Zettl A, Lee SS, Rudiger T, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol. 2002;117: 368-379.","DOI":"10.1309\/6UTX-GVC0-12ND-JJEU"},{"key":"2019111814522972200_REF19","doi-asserted-by":"crossref","unstructured":"Horenstein MG, Nador RG, Chadburn A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus\/human herpesvirus-8. Blood. 1997;90: 1186-1191.","DOI":"10.1182\/blood.V90.3.1186"},{"key":"2019111814522972200_REF20","doi-asserted-by":"crossref","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89: 1413-1420.","DOI":"10.1182\/blood.V89.4.1413"},{"key":"2019111814522972200_REF21","doi-asserted-by":"crossref","unstructured":"Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol. 1992;66: 122-131.","DOI":"10.1128\/JVI.66.1.122-131.1992"},{"key":"2019111814522972200_REF22","doi-asserted-by":"crossref","unstructured":"Kis LL, Nishikawa J, Takahara M, et al. The in vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1; CD40-ligand and IL-4 induces LMP-1 but not EBNA-2. Int J Cancer. 2005;113: 937-945.","DOI":"10.1002\/ijc.20654"},{"key":"2019111814522972200_REF23","doi-asserted-by":"crossref","unstructured":"Contreras-Salazar B, Ehlin-Henriksson B, Klein G, Masucci MG. Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. J Virol. 1990;64: 5441-5447.","DOI":"10.1128\/JVI.64.11.5441-5447.1990"},{"key":"2019111814522972200_REF24","doi-asserted-by":"crossref","unstructured":"Sairenji T, Ohnishi E, Inouye S, Kurata T. Induction of interleukin-10 on activation of Epstein-Barr virus in EBV-infected B-cell lines. Viral Immunol. 1998;11: 221-231.","DOI":"10.1089\/vim.1998.11.221"},{"key":"2019111814522972200_REF25","unstructured":"Ben-Bassat H, Goldblum N, Mitrani S, et al. Establishment in continuous culture of a new type of lymphocyte from a \u201cBurkitt like\u201d malignant lymphoma (line D.G.-75). Int J Cancer. 1977;19: 27-33."},{"key":"2019111814522972200_REF26","doi-asserted-by":"crossref","unstructured":"Maeda A, Kiss C, Chen F, et al. EBNA promoter usage in EBV-negative Burkitt lymphoma cell lines converted with a neomycin-resistant EBV strain. Int J Cancer. 2001;93: 714-719.","DOI":"10.1002\/ijc.1387"},{"key":"2019111814522972200_REF27","unstructured":"Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P. Surface IgM kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 1968;28: 1300-1310."},{"key":"2019111814522972200_REF28","doi-asserted-by":"crossref","unstructured":"Hinuma Y, Konn M, Yamaguchi J, et al. Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol. 1967;1: 1045-1051.","DOI":"10.1128\/JVI.1.5.1045-1051.1967"},{"key":"2019111814522972200_REF29","doi-asserted-by":"crossref","unstructured":"Kelly G, Bell A, Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med. 2002;8: 1098-1104.","DOI":"10.1038\/nm758"},{"key":"2019111814522972200_REF30","doi-asserted-by":"crossref","unstructured":"Gregory CD, Rowe M, Rickinson AB. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt lymphoma cell line. J Gen Virol. 1990;71: 1481-1495.","DOI":"10.1099\/0022-1317-71-7-1481"},{"key":"2019111814522972200_REF31","doi-asserted-by":"crossref","unstructured":"Takada K, Horinouchi K, Ono Y, et al. An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes. 1991;5: 147-156.","DOI":"10.1007\/BF00571929"},{"key":"2019111814522972200_REF32","unstructured":"Epstein MA, Achong BG, Barr YM, Zajac B, Henle G, Henle W. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Nat Cancer Inst. 1966;37: 547-559."},{"key":"2019111814522972200_REF33","doi-asserted-by":"crossref","unstructured":"Andersson ML, Stam NJ, Klein G, Ploegh HL, Masucci MG. Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells. Int J Cancer. 1991;47: 544-550.","DOI":"10.1002\/ijc.2910470412"},{"key":"2019111814522972200_REF34","doi-asserted-by":"crossref","unstructured":"Kempkes B, Spitkovsky D, Jansen-Durr P, et al. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J. 1995;14: 88-96.","DOI":"10.1002\/j.1460-2075.1995.tb06978.x"},{"key":"2019111814522972200_REF35","doi-asserted-by":"crossref","unstructured":"Polack A, Hortnagel K, Pajic A, et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci U S A. 1996;93: 10411-10416.","DOI":"10.1073\/pnas.93.19.10411"},{"key":"2019111814522972200_REF36","doi-asserted-by":"crossref","unstructured":"Nagata H, Konno A, Kimura N, et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T\/NK-cell lymphomas associated with the Epstein-Barr virus. Blood. 2001;97: 708-713.","DOI":"10.1182\/blood.V97.3.708"},{"key":"2019111814522972200_REF37","doi-asserted-by":"crossref","unstructured":"Tsuge I, Morishima T, Morita M, Kimura H, Kuzushima K, Matsuoka H. Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol. 1999;115: 385-392.","DOI":"10.1046\/j.1365-2249.1999.00836.x"},{"key":"2019111814522972200_REF38","doi-asserted-by":"crossref","unstructured":"Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative null and T cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer. 1977;19: 521-526.","DOI":"10.1002\/ijc.2910190505"},{"key":"2019111814522972200_REF39","doi-asserted-by":"crossref","unstructured":"Liu Y, de Waal Malefyt R, Briere F, et al. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol. 1997;158: 604-613.","DOI":"10.4049\/jimmunol.158.2.604"},{"key":"2019111814522972200_REF40","doi-asserted-by":"crossref","unstructured":"Dalla-Favera R, Migliazza A, Chang CC, et al. Molecular pathogenesis of B cell malignancy: the role of BCL-6. Curr Top Microbiol Immunol. 1999;246: 257-263.","DOI":"10.1007\/978-3-642-60162-0_32"},{"key":"2019111814522972200_REF41","doi-asserted-by":"crossref","unstructured":"Martin JM, Veis D, Korsmeyer SJ, Sugden B. Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2. J Virol. 1993;67: 5269-5278.","DOI":"10.1128\/JVI.67.9.5269-5278.1993"},{"key":"2019111814522972200_REF42","doi-asserted-by":"crossref","unstructured":"Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19: 683-765.","DOI":"10.1146\/annurev.immunol.19.1.683"},{"key":"2019111814522972200_REF43","doi-asserted-by":"crossref","unstructured":"Burdin N, Peronne C, Banchereau J, Rousset F. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med. 1993;177: 295-304.","DOI":"10.1084\/jem.177.2.295"},{"key":"2019111814522972200_REF44","doi-asserted-by":"crossref","unstructured":"Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer. 1994;57: 240-244.","DOI":"10.1002\/ijc.2910570218"},{"key":"2019111814522972200_REF45","doi-asserted-by":"crossref","unstructured":"Chen H, Hutt-Fletcher L, Cao L, Hayward SD. A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J Virol. 2003;77: 4139-4148.","DOI":"10.1128\/JVI.77.7.4139-4148.2003"},{"key":"2019111814522972200_REF46","doi-asserted-by":"crossref","unstructured":"Chen H, Lee JM, Zong Y, et al. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol. 2001;75: 2929-2937.","DOI":"10.1128\/JVI.75.6.2929-2937.2001"},{"key":"2019111814522972200_REF47","unstructured":"Stuart AD, Stewart JP, Arrand JR, Mackett M. The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes. Oncogene. 1995;11: 1711-1719."},{"key":"2019111814522972200_REF48","doi-asserted-by":"crossref","unstructured":"Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol. 1997;158: 4045-4051.","DOI":"10.4049\/jimmunol.158.9.4045"},{"key":"2019111814522972200_REF49","doi-asserted-by":"crossref","unstructured":"Zimber-Strobl U, Kempkes B, Marschall G, et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J. 1996;15: 7070-7078.","DOI":"10.1002\/j.1460-2075.1996.tb01098.x"},{"key":"2019111814522972200_REF50","doi-asserted-by":"crossref","unstructured":"Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992;89: 1890-1893.","DOI":"10.1073\/pnas.89.5.1890"},{"key":"2019111814522972200_REF51","doi-asserted-by":"crossref","unstructured":"Graziosi C, Gantt KR, Vaccarezza M, et al. Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc Natl Acad Sci U S A. 1996;93: 4386-4391.","DOI":"10.1073\/pnas.93.9.4386"},{"key":"2019111814522972200_REF52","doi-asserted-by":"crossref","unstructured":"Jason J, Archibald LK, Nwanyanwu OC, et al. Cytokines and malaria parasitemia. Clin Immunol. 2001;100: 208-218.","DOI":"10.1006\/clim.2001.5057"},{"key":"2019111814522972200_REF53","doi-asserted-by":"crossref","unstructured":"Khatri VP, Caligiuri MA. A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunol Immunother. 1998;46: 239-244.","DOI":"10.1007\/s002620050483"},{"key":"2019111814522972200_REF54","doi-asserted-by":"crossref","unstructured":"Boulland ML, Meignin V, Leroy-Viard K, et al. Human interleukin-10 expression in T\/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. Am J Pathol. 1998;153: 1229-1237.","DOI":"10.1016\/S0002-9440(10)65667-2"},{"key":"2019111814522972200_REF55","doi-asserted-by":"crossref","unstructured":"Shen L, Chiang AK, Liu WP, Li GD, Liang RH, Srivastava G. Expression of HLA class I, beta(2)-microglobulin, TAP1 and IL-10 in Epstein-Barr virus-associated nasal NK\/T-cell lymphoma: Implications for tumor immune escape mechanism. Int J Cancer. 2001;92: 692-696.","DOI":"10.1002\/1097-0215(20010601)92:5<692::AID-IJC1237>3.0.CO;2-Z"},{"key":"2019111814522972200_REF56","doi-asserted-by":"crossref","unstructured":"Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol. 2003;3: 801-812.","DOI":"10.1038\/nri1201"},{"key":"2019111814522972200_REF57","doi-asserted-by":"crossref","unstructured":"Ohashi K, Miki T, Hirosawa S, Aoki N. Characterization of the promoter region of human BCL-6 gene. Biochem Biophys Res Commun. 1995;214: 461-467.","DOI":"10.1006\/bbrc.1995.2309"},{"key":"2019111814522972200_REF58","doi-asserted-by":"crossref","unstructured":"Scheeren FA, Naspetti M, Diehl S, et al. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol. 2005;6: 303-313.","DOI":"10.1038\/ni1172"},{"key":"2019111814522972200_REF59","doi-asserted-by":"crossref","unstructured":"Babcock GJ, Thorley-Lawson DA. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A. 2000;97: 12250-12255.","DOI":"10.1073\/pnas.200366597"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/7\/2928\/1338754\/zh800706002928.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/7\/2928\/1338754\/zh800706002928.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T20:10:26Z","timestamp":1683317426000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/7\/2928\/132064\/IL10-can-induce-the-expression-of-EBVencoded"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,1]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2569","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,1]]}}}